Tags:BioTechDevelopmentHealthTechHumanInformationLifeMedTechProductPublicScience
Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Our therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, we are developing a series of first-in-class therapeutics. For more information, visit www.GeminiTherapeutics.com
Location: United States, Massachusetts, Cambridge
Member count: 11-50
Total raised: $42.5M
Founded date: 2015

Investors 5

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
17.10.2017Series A$42.5MOrbiMedmedcitynew...

Mentions in press and media 8

DateTitleDescriptionCategoryAuthorSource
25.02.2021Biotech an...The firm, which now has over $...-Steven Loe...vator.tv/n...
18.10.2017Term Sheet...5 Qs WITH A DEALMAKER Good mo...--fortune.co...
18.10.2017Gemini The...Atlas Venture, Lightstone Vent...--medcitynew...
17.10.2017OrbiMed Le...CAMBRIDGE, Mass.--(BUSINESS WI...--citybizlis...
17.10.2017Gemini The... CAMBRIDGE, MA, Gemini Therap...--vcnewsdail...
17.10.2017Gemini The...Gemini Therapeutics, a Cambrid...USA-finsmes.co...
17.10.2017Gemini The...CAMBRIDGE, Mass.--(BUSINESS WI...--citybizlis...
-Gemini The...Fundus photo of macular scarri...--medcitynew...